Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3002 in advanced cancers
NCT06662760Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3002 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
TQB3002
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06662760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662760.